CN Patent

CN110960486B — 一种溴甲纳曲酮注射液组合物

Assigned to Beijing Kawin Technology Share Holding Co ltd · Expires 2022-05-13 · 4y expired

What this patent protects

本发明提供了一种溴甲纳曲酮注射液组合物，每1000ml所述组合物的组成为：溴甲纳曲酮20g，色氨酸0.01‑1.0g，依地酸钙钠0.1‑2.0g；枸橼酸0.01‑0.5g，氯化钠5.5‑7.5g；盐酸调节pH至3.0‑5.0，注射用水适量。本发明的溴甲纳曲酮注射液具有有关物质含量低、稳定性高等优点。

USPTO Abstract

本发明提供了一种溴甲纳曲酮注射液组合物，每1000ml所述组合物的组成为：溴甲纳曲酮20g，色氨酸0.01‑1.0g，依地酸钙钠0.1‑2.0g；枸橼酸0.01‑0.5g，氯化钠5.5‑7.5g；盐酸调节pH至3.0‑5.0，注射用水适量。本发明的溴甲纳曲酮注射液具有有关物质含量低、稳定性高等优点。

Drugs covered by this patent

methylnaltrexone-bromide (METHYLNALTREXONE BROMIDE)

Patent Metadata

Patent number: CN110960486B
Jurisdiction: CN
Classification: —
Expires: 2022-05-13
Drug substance claim: No
Drug product claim: No
Assignee: Beijing Kawin Technology Share Holding Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.